All In Biotech

Drug Trial Radar · NCT06500026

A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)

A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer After Failure of Anti-PD-1/PD-L1 Monoclonal Antibodies and Platinum-based Chemotherapy

Last checked: Nov 19, 2026Latest source record: Apr 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 722 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

722

Actual

Start

Aug 7, 2024

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Sponsor type
Industry
Collaborators
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
First posted
Jul 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with recurrent small cell lung cancer after failure of anti-PD-1/PD-L1 Monoclonal Antibodies and platinum-based chemotherapy.

Conditions

  • Small Cell Lung Cancer

Interventions

  • BL-B01D1Drug

    Administration by intravenous infusion for a cycle of 3 weeks.

  • TopotecanDrug

    Administration by intravenous infusion for a cycle of 3 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (OS)Time frame: Up to approximately 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.